Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety,
tolerability and pharmacokinetics of a single ascending doses (SAD) and multiple ascending
doses (MAD) of Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination
(ALX-009) in healthy male volunteers and patients suffering from cystic fibrosis (CF) and
non-CF bronchiectasis (NCFBE).